Company intelligence / Profile preview

Xspray Pharma

Ownership: Private
Development stage: NDA

Overview

Xspray Pharma develops improved amorphous versions of marketed protein kinase inhibitors (PKIs) for cancer treatment. Their lead product Dasynoc (dasatinib) is awaiting final FDA approval with anticipated launch on September 1, 2024. Their second product candidate XS003 (nilotinib) has demonstrated matching bioavailability with Tasigna at a reduced dose and is expected to be submitted to FDA in first half of 2025.[1][5][7]

Therapeutic areas: Oncology
Modalities: Small moleculesamorphous solid dispersion (ASD) formulations
Industry: Biotech

Drug pipeline

5 assets

XS003

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Xspray Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xspray Pharma.

Explore the full profile